Aimmune Therapeutics, Inc.

Form 3

November 23, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement Aimmune Therapeutics, Inc. [AIMT] A Nestle Health Science US (Month/Day/Year) Holdings, Inc. 11/23/2016 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 383 MAIN AVE., 5TH FLOOR (Check all applicable) (Street) 6. Individual or Joint/Group Filing(Check Applicable Line) Director __X__ 10% Owner Form filed by One Reporting Officer Other Person NORWALK, Â CTÂ 06851 (give title below) (specify below) _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership (Instr. 4) Ownership (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) $0^{(1)}$ Common Stock 7,552,084 I Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of

information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Title	Security	Direct (D)	

Edgar Filing: Aimmune Therapeutics, Inc. - Form 3

Date	Expiration	Amount or	or Indirect
Exercisable	Date	Number of	(I)
		Shares	(Instr. 5)

Reporting Owners

Reporting Owner Name / Address	Relationships				
reporting 6 mar runner, runners	Director	10% Owner	Officer	Othe	
Nestle Health Science US Holdings, Inc. 383 MAIN AVE., 5TH FLOOR NORWALK, CT 06851	Â	ÂΧ	Â	Â	
NESTLE SA AVE NESTLE 55 VEVEY, V8 CH-1800	Â	ÂΧ	Â	Â	
NIMCO US, Inc. 383 MAIN AVE, 5TH FLOOR NORWALK, CT 06851	Â	ÂX	Â	Â	
Signatures					
/s/ James Pepin, President		11/23/2016			
**Signature of Reporting Person			Date		
/s/ David P. Frick, Secretary to the Board of Directors		11/23/2016			
**Signature of Reporting Person			Date		
/s/ Gary Kirschenbaum, Vice President		11/2	23/2016)	
**Signature of Reporting Person		Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Held by Nestle Health Science US Holdings, Inc. Nestle Health Science US Holdings, Inc. is wholly owned subsidiary of NIMCO US,
Inc., which is a wholly owned subsidiary of Nestle S.A., a publicly traded company. Each of these entities may be deemed to share voting and investment power with respect to all shares held by Nestle Health Science US Holdings, Inc. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2